Home | Publications | Biotechnology place holder
place holder place holder

Biotechnology

World Biotech Market 2005, The


Publication Date   June 2005
Publisher   Visiongain
Product Type   Report
Pages   262
ISBN Number   not applicable
Product Code   VIS020
Ask a question about this product?

Price £4,999.00

approximately: $9,341 | €6,340

Summary


Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the client will receive an email with information on accessing their purchase.

The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science driven by the 2001 human genome project is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis to multiple sclerosis and orphan diseases such as Fabry's disease.

Visiongain values the 2005 biopharma market at $70.8bn. Having grown 16.5% from 2004's revenues of $60.7bn, double-digit growth of the market will continue to the end of the decade. Composed of 9 major therapeutic areas including oncology, anti-infectives, vaccines and the market leader blood disorders, the market by 2010 is expected to represent 17% of all prescriptions written compared with 2004's 12%. At this pace of growth, biotech is now outgrowing Big Pharma.

At present the US dominates the biotech market and will do so for the rest of the forecast period. Japan and the EU will see a fall in global market share, whilst the Asia-Pacific region will see high levels of unprecedented growth.

Biotech companies however still face major challenges. The threat of the emergence of biogenerics is mounting, with 11 products facing patent expiry before 2007- 5 of which are blockbusters. The Australian approval of his Sandoz's Omnitrope hGH product is paving the way, and increasing pressure upon EU and US regulatory agencies to give the go ahead to biogenerics.

Aims, Scope and Format of World Biotech, 2005

This report begins by introducing biopharmaceuticals and the technologies involved in their development and manufacture. The market is also introduced, with a brief overview of its history. Chapter 3 provides an overview of disease information that biopharmaceuticals treat.

The report then goes on to value the 2003/2004 market for biopharmaceuticals, including the leading brands, drug classes and the comapanies dominating the market.

The report then examines pipelines for each therapeutic class of biopharmaceuticals, and goes on to highlight the sales potential for all leading products and key pipeline candidates from 2003 to 2010.

Forecasts for each biopharmaceutical therapeutic area is provided in chapter 7, with in-depth analysis and forecasting by drug type.

A summary chapter of the 2010 market is then provided in Chapter 8, illustrating the predicted leading brands and therapeutic categories on the market by 2010.

The threat of biogenerics is examined and the potential value of the biogeneric market is detailed in Chapter 10, with revenues for the six major biologics under patent expiry threat.

This is followed by a detailed discussion regarding the challenges the biopharma market will face in the coming years. Each challenge is detailed with strategies that can be used by biotech companies to overcome them. The major challenge of venture captalism within bitoech is discussed in Chapter 12.

Chapter 13 details the global biopharmaceutical market from 2003 to 2010 by country/region. Market share in 2003 and 2010 is compared for the US, EU, Japan and the Asia-Pacific region. Forecast revenues are also provided for each of these countries/regions.

The report then goes on to discuss the impact of the human genome project on the biopharmaceutical market. World Biotech, 2005 ends with a concise conclusion, summarising the main issues analysed within the report.

World Biotech, 2005 represents a key tool for companies wishing to enter into or expand into the biopharma market. The reader will be left with a clear idea of therapeutic targets currently under

development within the field, whom is responsible for this development and the competition that companies will face from current and future products.

Content


  • 1. Executive Summary of World Biotech Market, 2005
    • 1.1 Abstract of Biotech, 2005
    • 1.2 Aims, Scope and Format of Biotech, 2005
  • 2. Introduction to Biotechnology
    • 2.1 What is Biotechnology?
    • 2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around
    • 2.3 Biotechnologies Used and Their Applications to Pharma
      • 2.3.1 Bioprocessing Technology
      • 2.3.2 Monoclonal Antibodies
      • 2.3.3 Recombinant DNA Technology
      • 2.3.4 Cloning
        • 2.3.4.1 Molecular Cloning
        • 2.3.4.2 Cellular Cloning
        • 2.3.4.3 Animal Cloning
        • 2.3.4.4 Protein Engineering
    • 2.4 The Future Biopharmaceutical Market
      • 2.4.1 Biopharmaceutical 2004 Market Capatilisation Worth $311bn
      • 2.4.2 Over 7000 Biotechnology Patents Granted Per Annum Since 1998
      • 2.4.3 2004 Witnessed 54 New Biopharmaceutical FDA Approvals
      • 2.4.4 Biopharmaceuticals Share 12.5% of 2004 Global Prescriptions
  • 3. Diseases Treated by Biopharmaceuticals
    • 3.1 Biopharmaceuticals Are Versatile Agents
    • 3.2 Orphan Diseases Are A Major Target of Biotech: 3 Out of 10 2004 Orphan Disease Approvals Were Biopharmaceuticals
    • 3.3 Overview to Major and Orphan Diseases Treated by Biopharmaceuticals, 2005
  • 4. Overview of Biopharmaceuticals Market, 2003-2004
    • 4.1 Monoclonal Antibodies: Leading Class of Biopharmaceuticals in 2004 With Sales of $13bn
    • 4.2 Blood Disorders Share Over A Quarter of 2004 Biopharmaceuticals Market
    • 4.3 Biopharmaceuticals 2004 Market Worth a Staggering $55.7bn
    • 4.4 The Top 20 Selling Biologics of 2004 Accounted For 62% of Total Revenues
    • 4.5 Top 3 Biopharmaceuticals Products of 2004 Sold Over $9bn
      • 4.5.1 Procrit/Eprex - The Number One Biopharmaceutical Struggles at the Top
      • 4.5.2 Risperdal Performs Well Thanks to New Delivery Technology
      • 4.5.3 Epogen: The Third Best Selling Biopharmaceutical of 2004
    • 4.6 Santura: The Highest Earning Newcomer of 2004
  • 5. Company Revenues and Market Share, 2004
    • 5.1 Amgen: The Reign Continues With A 17% Share of 2004 Market
      • 5.1.1 Who Are Amgen?
    • 5.2 Biotech Company Winners and Losers in 2004
    • 5.3 BMS: The Best Company Newcomer of 2004
  • 6. Biopharmaceutical Pipeline
    • 6.1 Technology Driving Biopharma Pipeline
    • 6.2 Biotech Targeting Chronic Illness
    • 6.3 Arthritis Biopharmaceutical Pipeline, 2005
    • 6.4 MS Biopharmaceutical Pipeline, 2005
    • 6.5 Late-Stage Biopharmaceutical Oncology Pipeline, 2005
    • 6.6 Late Stage Biopharmaceutical Vaccine Pipeline, 2005
    • 6.7 Blood Disorders Biopharmaceutical Pipeline, 2005
    • 6.8 Late Stage Biopharmaceutical Endocrine Pipeline, 2005
    • 6.9 Anti-Infectives Biopharmaceutical Pipeline, 2005
    • 6.10 Enzyme Deficiency Biopharmaceutical Pipeline, 2005
    • 6.11 Late Stage Biopharmaceutical Ophthalmic Pipeline, 2005
    • 6.12 Late Stage Biopharmaceutical 'Other' Pipeline, 2005
  • 7. Biopharmaceutical Market Forecast by Therapeutic Area, 2003-2010
    • 7.1 Blood Disorders
    • 7.2 Endocrine Disorders
    • 7.3 Multiple Sclerosis
    • 7.4 Oncology
    • 7.5 Anti Infectives
    • 7.6 Enzyme Deficiency Disorders
    • 7.7 Vaccines
    • 7.8 Arthritis
    • 7.9 Ophthalmics
    • 7.10 Others
    • 7.11 Biopharmaceutical Market Set To Almost Triple By 2010
  • 8. Summary of 2010 Biopharmaceuticals Market
    • 8.1 Aransep: The Top Selling Biopharmaceutical of 2010 With Sales of $5.2bn
    • 8.2 Blood Disorders Will Remain Market Leaders
    • 8.3 Ophthalmic Biopharmaceuticals: The Fastest Growing Therapeutic Class 2003-2010
    • 8.4 By 2010 Biopharmaceuticals Will Account for Over 17% of All Drug Prescriptions
  • 9. Introduction to Biogenerics
    • 9.1 What are Biogenerics?
    • 9.2 The Biogeneric Threat Looms Large
    • 9.3 All Change in 2003: CDER to CBER
    • 9.4 How are Approval Pathways Limiting the Development of Biogenerics?
    • 9.5 Omnitrope Approved in Australia, Will Europe and the US Follow?
    • 9.6 High Cost of Market Entry
    • 9.7 Manufacturing Capacity Problems
    • 9.8 Biopharma Vs Biogenerics: The Fight Continues
      • 9.8.1 Bioequivalence or Biosimilarity?
    • 9.9 Will the Benefits of Biogenerics be as Great as Anticipated?
    • 9.10 How Imminent is the Threat from Biogeneric Competition?
  • 10. The Potential Biogeneric Market
    • 10.1 $13bn of Biopharmaceuticals To Lose Patency Protection By 2007
    • 10.2 Eleven Biopharmaceuticals to Face Patent Expiry by 2007
    • 10.3 High-Revenue Generating Biopharmaceuticals Face Patent Expiry Before 2007
    • 10.4 High-Profile Biopharmaceuticals With Patent Expirations Before 2007 Revenue Forecast, 2003-2010
    • 10.5 Erythropoiteins Are Most At Risk To Biogeneric Competition
  • 11. Biopharmaceutical Market Challenges
    • 11.1 BioTech's Delivery Challenge
      • 11.1.1 Pulmonary Delivery: An Innovative Alternative to the Needle?
      • 11.1.2 The Major Issues of the Pulmonary Pathway
      • 11.1.3 Does Protein Formulation Affect Pulmonary Delivery?
      • 11.1.4 Does Pulmonary Drug Delivery Have a Future?
      • 11.1.5 Pegylated Forms Set to Revolutionise Delivery
      • 11.1.6 Pegylation Can Extend Patencies! The Filgrastim Example
      • 11.1.7 Transdermal Technologies
      • 11.1.8 Microneedles for Transdermal Delivery of Vaccines
      • 11.1.9 Nasal Delivery Is Demonstrating Promise
      • 11.1.10 Moving Towards Pills? Altus' Unique Technology
      • 11.1.11 New Delivery Technologies: A Pharmacy or Medical Benefit?
      • 11.1.12 Innovative Insulin Delivery Technology: The Race is On!
      • 11.1.13 Numerous Potential Blockbusting NonInjected Insulins Set to Arrive 2005-2009
    • 11.2 Manufacturing Capacity Shortfall
      • 11.2.1 Why is There a Shortfall in Manufacturing Capacity for Biopharmaceuticals?
      • 11.2.2 Make Vs. Buy: The 1980s BioIndustry
      • 11.2.3 CMO Manufacturing Capacity was Adequate for the Supply of Clinical Materials Only
      • 11.2.4 Late-Stage Products have absorbed CMO Clinical Manufacturing Capacity
      • 11.2.5 How is the Manufacturing Capacity Shortfall Being Overcome?
      • 11.2.6 Does the Future for Biopharmaceutical Manufacturing Lie with Transgenics?
    • 11.3 The Cost of Biopharmaceuticals
      • 11.3.1 The Top Five Biopharmaceuticals Each cost at Least $10K Per Patient Per Annum
      • 11.3.2 Monoclonal Antibodies and CSF's High Costs Reflect Production Difficulties
      • 11.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in the Future
    • 11.4 Acquiring Capital
      • 11.4.1 Financing of Biotech Companies in 2003 Neared $17bn
    • 11.5 Reliance Upon University/Company Collaborations
      • 11.5.1 The Need For Collaboration
      • 11.5.2 Biotech's Increasing Role of Commercialising University Research
      • 11.5.3 Future Biotech Innovation Lies With Academia
      • 11.5.4 The Risky Path from Bench to Market
      • 11.5.5 Collaboration Strategies & Becoming the Partner of Choice
        • 11.5.5.1 Objectives That Support Strategic Goals
        • 11.5.5.2 Understanding the Value Brought to an Alliance
        • 11.5.5.3 Identifying and Understanding Potential Partners
        • 11.5.5.4 Due Diligence
        • 11.5.5.5 Promoting Capabilities to Potential Partners
        • 11.5.5.6 Maintaining a Relationship Through Structured Interactions
        • 11.5.5.7 Gaining Competitive Advantage
        • 11.5.5.8 Collaboration Management: Developing and Maintain A Deal
        • 11.5.5.9 Strategic Goals to Consider
    • 11.6 Regulatory Issues
      • 11.6.1 Biopharmaceuticals and the FDA
      • 11.6.2 FDA Improving Upon Biologics Approval Wait
    • 11.7 Biogeneric Threat
    • 11.8 Dependence upon Venture Capital Investment
    • 11.9 Drivers and Restraints of Biopharmaceutical Market Growth
      • 11.9.1 Drivers
      • 11.9.2 Restraints
  • 12. Venture Capital Investment & Biotech
    • 12.1 What is Venture Capital Investment?
    • 12.2 What does VC Offer?
    • 12.3 What Do Venture Capitalists Do?
    • 12.4 Who Are Venture Capitalists?
      • 12.4.1 Banks as Venture Capitalists
      • 12.4.2 Business Angels (Wealthy Individuals) as Venture Capitalists
      • 12.4.3 Corporate or Direct Investors as Venture Capitalists
      • 12.4.4 Government Grants and Governments as Venture Capitalists
      • 12.4.5 Venture Capital Firms
      • 12.4.6 Other Types of Venture Capitalists
    • 12.5 Why Do Biotech Companies Need VC Funding?
    • 12.6 Venture Capital Investment in the US Biotech Market
      • 12.6.1 US VC Investment Now Recovering Following Stockmarket Crash in 2000
      • 12.6.2 329 US Biotech VC Investments Made in 2004, Providing Over $3.8bn
      • 12.6.3 Synta Provides 2004's Largest US Investment Sum With $80m
      • 12.6.4 MPM Capital 2004's Most Active US Biotech VC Firm
      • 12.6.5 Company Expansion Stage is the Most Favourable for VC Investment
    • 12.7 Increase in VC Funding of European Biotech
    • 12.8 PE European Investments in Biotech Followed Similar Trends as in the US
    • 12.9 European PE Biotech Investments are a Small Part of the Funding Market
  • 13. Conclusion: Big Pharma Must Invest into Biotech Arena
    • 13.1 Conclusion
  • List of Tables
    • Table 2.1 Definitions of Selected Biopharmaceuticals
    • Table 2.2 Summary of Biotechnologies
    • Table 3.1: Overview to Major Diseases and Selected Orphan Diseases Treated by Biopharmaceuticals, 2005
    • Table 4.6: Revenue ($m) for Classes of Technology Biopharmaceuticals, 2004
    • Table 4.1 Biopharmaceutical Revenues ($m) by Technology Class, 2004
    • Table 4.2: Vaccine Products in 2004 Market
    • Table 4.3 Monoclonal Antibody Products % Growth Rates, 2004
    • Table 4.4 Biopharmaceuticals Revenue ($m) by Therapeutic Area, 2004
    • Table 4.5: Blood Modifiers by Revenue ($m), 2004
    • Table 4.6: Biopharmaceutical Revenues ($m) in 2003 Top 400 by Drug Type, 2004
    • Table 4.7 Total Biopharmaceutical Revenues 2003 & 2004
    • Table 4.8: Top 20 Selling Biopharmaceuticals, 2004
    • Table 4.9: Revenues of Newcomers to 2004 Biopharmaceuticals Market
    • Table 5.1: Biopharmaceutical Company Revenues ($m), 2003 & 2004, and 2004 Company Market Share (%)
    • Table 5.2: Roche Biopharmaceutical Portfolio By Revenue ($m), 2003 and 2004
    • Table 5.3: GSK Biopharmaceutical Portfolio By Revenue ($m), 2003 and 2004
    • Table 5.4: Schering Plough Biopharmaceutical Portfolio By Revenue ($m), 2003 and 2004
    • Table 5.5: Amgen's Product Portfolio By Revenue ($m), 2004
    • Table 5.6: Amgen Total Revenue ($bn), 2001-2004
    • Table 6.1: Overview of Biotech Pipeline By Biotechnology Type, 2005
    • Table 6.2: Arthritis Biopharmaceutical Pipeline, 2005
    • Table 6.3: MS Biopharmaceutical Pipeline, 2005
    • Table 6.4: Late Stage Biopharmaceutical Oncology Pipeline
    • Table 6.5: Late Stage Biopharmaceutical Vaccine Pipeline, 2005
    • Table 6.6: Blood Disorders Biopharmaceuticals Pipeline, 2005
    • Table 6.7 Late-Stage Biopharmaceutical Endocrine Pipeline, 2005
    • Table 6.8 Anti-Infective Biopharmaceutical Pipeline, 2005
    • Table 6.9 Enzyme Deficiency Disorder Biopharmaceutical Pipeline, 2005
    • Table 6.10 Late-Stage Biopharmaceutical Ophthalmic Pipeline, 2005
    • Table 6.11 Late-Stage Biopharmaceutical Others Pipeline, 2005
    • Table 7.1: Treatment of Blood Disorder by Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.2: Total World Biopharmaceutical Blood Disorder Market Forecast ($m), 2003-2010
    • Table 7.3 Endocrine Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.4: Total World Biopharmaceutical Endocrine Market Forecast ($m), 2003-2010
    • Table 7.5: Multiple Sclerosis Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.6: Total World Biopharmaceutical Multiple Sclerosis Market Forecast ($m), 2003-2010
    • Table 7.7: Oncology Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.8: Total World Biopharmaceutical Oncology Market Forecast ($m), 2003-2010
    • Table 7.9: Anti-Infective Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.10:Total World Biopharmaceutical Anti-Infectives Market Forecast ($m), 2003-2010
    • Table 7.11: Enzyme Replacement Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.12: Total World Biopharmaceutical Enzyme Replacement Market Forecast ($m), 2003-2010
    • Table 7.13: Vaccine Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.14:Total World Biopharmaceutical Vaccine Market Forecast ($m), 2003-2010
    • Table 7.15: Arthritis Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.16:Total World Biopharmaceutical Arthritis Market Forecast ($m), 2003-2010
    • Table 7.17: Ophthalmic Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.18: Total World Biopharmaceutical Ophthalmic Market Forecast ($m), 2003-2010
    • Table 7.19: Other Biopharmaceutical by Revenue ($m), 2003 and 2004
    • Table 7.20: Total World Biopharmaceutical Other Market Forecast ($m), 2003-2010
    • Table 7.21: Total Global Biopharmaceutical Market Revenue ($bn) Forecast 2003-2010
    • Table 8.1: Top 10 Selling Biopharmaceuticals of 2010
    • Table 8.2: Total Global Biopharmaceutical Market Revenue ($bn) Forecast by Therapeutic Class, 2003-2010
    • Table 8.3: Market Share of Biopharmaceuticals By Therapeutic Class, 2003 & 2010 Comparison
    • Table 8.4: Biopharmaceuticals CAGR% By Therapeutic Class, 2003-2010
    • Table 8.5: Revenues ($bn) of Total Prescriptions By Technology Type 1999-2010
    • Table 9.1 Biopharmaceuticals Facing Patent Expiry and their Biogeneric Status, 2005
    • Table 9.2: Key Supporters For Biogenerics And Their Opinions
    • Table 9.3: Key Opponents Arguments Against Biogenerics
    • Table 10.1: Biopharmaceuticals Facing Patency Expiry by 2007
    • Table 10.2 Revenue ($m) Forecast of 6 High Profile Biopharmaceuticals Facing Patency Expiry Before 2007, 2003-2010
    • Table 11.1 Mode of Administration of 2004's Top 5 Biopharmaceuticals
    • Table 11.2: Expected Blockbuster Noninjected Insulins From 2005
    • Table 11.3: Total European IPOs by Country, 2003
    • Table 12.1: US and European VC Investment ($m) Into Biotech Companies, 1997-2003
    • Table 12.2: Total US VC Investment ($bn), 1994-2004
    • Table 12.3: Biopharmaceutical Venture Capital Investments By Quarter, 2003 vs 2004
    • Table 12.4: Number of Biopharmaceutical Venture Capital Investments By Quarter, 2003 vs 2004
    • Table 12.5: Top 5 Largest Biotech Investments ($m) by Company, 2004
    • Table 12.6: Most Active Biotech Venture Capital Firms of 2004
    • Table 12.7: US VC Investments by Company Stage, 2003-2004
    • Table 12.8: PE European Investments ($m) in Biotech, 1997-2003
  • List of Graphs
    • Graph 2.1:Biopharmaceutical Market Capatilsation ($bn), 1994-2004
    • Graph 2.2: Total Number of Biotechnology Patents Granted: 1992-2002
    • Graph 2.3: Number of New Biological FDA Approvals: 1994-2004
    • Graph 2.4 Biopharmaceuticals Share of Global Prescriptions 1999-2004
    • Graph 4.1: Global Sales ($m) of Biopharmaceuticals by Technology Class, 2004
    • Graph 4.2: Global Sales ($m) of Biopharmaceuticals by Therapeutic Area, 2004
    • Graph 4.3: Total Global Biopharmaceutical Revenue, 2003-2004
    • Graph 4.4: Top 20 Selling Biopharmaceuticals, 2004
    • Graph 4.5: Global Procrit/Eprex Sales ($m), 2001-2004
    • Graph 4.6: Global Risperdal Sales ($m), 2001-2004
    • Graph 4.7: Global Epogen Sales ($m), 2001-2004
    • Graph 4.8: Revenues for Newcomers to the Global Biopharmaceutical Market, 2004
    • Graph 5.1: Biotech Company Revenues ($m), 2003 & 2004
    • Graph 5.2: Company % Change in Revenue, 2003-2004
    • Graph 5.3: 2004 Company Newcomers to Biopharmaceuticals Market By Revenue ($m)
    • Graph 5.4: Amgen Company Revenue ($bn), 2001-2004
    • Graph 5.5: Amgen Change in Revenue (%), 2002-2004
    • Graph 6.1: Biopharmaceutical Pipeline by Biotechnology Type, 2005
    • Graph 6.2: Duration of Therapies of Biotech Pipeline Products in Late-Stage Development, 2003
    • Graph 7.1: Total World Biopharmaceutical Blood Disorder Market Forecast ($bn), 2003-2010
    • Graph 7.2: Total World Biopharmaceutical Blood Disorder Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.3: Total World Biopharmaceutical Endocrine Market Forecast ($bn), 2003-2010
    • Graph 7.4: Total World Biopharmaceutical Endocrine Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.5: Total World Biopharmaceutical Multiple Sclerosis Market Forecast ($bn), 2003-2010
    • Graph 7.6: Total World Biopharmaceutical Multiple Sclerosis Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.7: Total World Biopharmaceutical Oncology Market Forecast ($bn), 2003-2010
    • Graph 7.8: Total World Biopharmaceutical Oncology Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.9: Total World Biopharmaceutical Anti- Infectives Market Forecast ($bn), 2003-2010
    • Graph 7.10: Total World Biopharmaceutical Anti-Infectives Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.11:Total World Biopharmaceutical Enzyme Replacement Market Forecast ($bn), 2003-2010
    • Graph 7.12: Total World Biopharmaceutical Enzyme Replacement Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.13: Total World Biopharmaceutical Vaccine Market Forecast ($bn), 2003-2010
    • Graph 7.14: Total World Biopharmaceutical Vaccine Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.15: Total World Biopharmaceutical Arthritis Market Forecast ($bn), 2003-2010
    • Graph 7.16: Total World Biopharmaceutical Arthritis Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.17: Total World Biopharmaceutical Ophthalmic Market Forecast ($bn), 2003-2010
    • Graph 7.18: Total World Biopharmaceutical Ophthalmic Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.19: Total World Biopharmaceutical Other Market Forecast ($bn), 2003-2010
    • Graph 7.20: Total World Biopharmaceutical Other Market Revenue Growth Forecast (%), 2004-2010
    • Graph 7.21: Total Global Biopharmaceutical Market Revenue Growth (%), 2004-2010
    • Graph 7.22: Total Global Biopharmaceutical Market Revenue ($bn) Forecast 2003-2010
    • Graph 8.1: Top-10 Selling Biopharmaceuticals of 2010 ($m)
    • Graph 8.2: Total Global Biopharmaceutical Market Revenue ($bn) Forecast by Therapeutic Class, 2003-2010
    • Graph 8.3: % Change of Market Share By Therapeutic Area, 2003 & 2010
    • Graph 8.4: Biopharmaceuticals CAGR% By Therapeutic Class, 2003-2010
    • Graph 8.5: Biopharmaceutical Revenue ($bn) of Total Prescriptions, 1999-2010
    • Graph 10.1 Targets Of Biogeneric Companies By Drug Class
    • Graph 10.2: Total Revenue ($bn) of Six High Profile Biopharmaceuticals Facing Patent Expiry By 2007, 2003-2010
    • Graph 10.3: Total Revenue Growth (%) of Six High Profile Biopharmaceuticals Facing Patent Expiry By 2007, 2003-2010
    • Graph 11.1 Cost of Top Five Selling Biopharmaceuticals of 2004 ($ Per Patient Per Year)
    • Graph 11.2: Total Financing of Biopharmaceuticals ($bn), 2000-2003
    • Graph 11.3: Number of Pharmaceutical Alliances Formed By Party, 1997-2001
    • Graph 11.4: % of Alliances Formed With Licensing, By Party During 2001
    • Graph 11.5: % of Alliances Formed With Development/Co-Development, By Party During 2001
    • Graph 11.6: % of Alliances Formed With Research, By Party During 2001
    • Graph 11.7: Mean FDA Approval Time For New Biopharmaceuticals, 2000-2004
    • Graph 12.1: US and European VC Investment ($m) Into Biotech Companies, 1997-2003
    • Graph 12.2: Total US VC Investment ($bn), 1994-2004
    • Graph 12.3: % Change From Previous Year of Total US VC Investment, 1995- 2004
    • Graph 12.4: Total Biotech VC Investments ($m) By Quarter, 2003-2004
    • Graph 12.5: % Change of Biotech VC Investments By Quarter, 2003-2004
    • Graph 12.6: Number of Biotech VC Investments By Quarter, 2003 -2004
    • Graph 12.7: % Change of Number of Biotech VC Investments By Quarter, 2003 -2004
    • Graph 12.8: PE European Investments ($m) in Biotech, 1997-2003
    • Graph 12.9: % Change of PE European Investments ($m) in Biotech, 1998-2003
  • List of Charts
    • Chart 4.1: Biopharmaceutical Market Share (%) by Class, 2004
    • Chart 4.2: Biopharmaceutical Market Share (%) by Therapeutic Class, 2004
    • Chart 4.3 Top 20 Selling Biologics Share (%) of Total Biopharmaceuticals Market
    • Chart 4.4: Global Market Share (%) for the Top 3 Selling Biologics, 2004
    • Chart 5.1: 2004 Market Share (%) By Company
    • Chart 6.1: Pipeline share (%) of Biopharmaceuticals Duration of Therapy, 2003
    • Chart 11.1: Biopharmaceutical Industry Financing By Source, 2003
    • Chart 8.1: Market Share of the Top-10 Selling Biopharmaceuticals (%), 2010
    • Chart 8.2: Biopharmaceutical Therapeutic Class Market Share (%), 2003
    • Chart 8.3: Biopharmaceutical Therapeutic Class Market Share (%), 2010
    • Chart 10.1: Six High Profile Biopharmaceuticals Revenue Share (%) of Total Biopharmaceuticals Facing Patency Expiry By 2007, 2004
    • Chart 12.1: US VC Investments in Biotech by Company Stage, 2004
  • List of Companies Mentioned
    • 3M
    • Abbott Laboratories
    • Abgenix
    • Abraxis
    • Addex Pharmaceuticals
    • Alfacell
    • AlgoRx
    • Allergan
    • Alta Partners
    • Amarillo
    • American Pharma Partners
    • Amgen
    • Antisoma
    • Ardana
    • Arpida
    • AstraZeneca
    • Aventis
    • Aventis
    • Basilea
    • Bausch & Lomb
    • Bayer
    • Biogen Idec
    • Biomarin
    • Biomura
    • BioScience Contract Production
    • BMS
    • Boehringer-Ingelheim.
    • Bone Care
    • Borealis Ventures
    • Boston Millennia Partners
    • Boston Scientific
    • Burrill & Company
    • Cangene
    • Cell Genesys
    • Celltech
    • Centocor
    • Chiron
    • Chugai
    • Connetics Corp
    • Corus
    • CoTherix
    • Covance
    • CTI
    • Daiichi
    • Danek
    • Dendreon
    • Domain Associates
    • DSM
    • DynPort Vaccine
    • Elan Corp
    • Eli Lilly
    • Endo Pharmaceuticals
    • Enron
    • Evotec
    • Eximias
    • Eyetech
    • Fletcher Spaght Ventures
    • Galderma
    • Genentech
    • Genrex Biotech
    • Genzyme
    • Gilead Sciences
    • GlycoFi
    • Goodwin Biotechnology
    • GSK
    • Human Genome Sciences
    • ImClone Systems Inc
    • Indevus
    • Intarcia
    • Intercell
    • ISTA
    • JDS
    • Jerini
    • Johnson & Johnson
    • Lonza
    • Lundbeck
    • Mallinckrodt
    • Maxgen
    • Maxim
    • MedImmune
    • Medtronic
    • Merck
    • Millennium Pharmaceuticals
    • MPM Capital
    • NCI
    • Nobex Corp
    • Novartis
    • Novo Nordisk
    • NPS
    • Odyssey
    • OSI
    • Paion
    • Peninsula Equity Partners
    • Pfizer
    • Pharmion Corp
    • Polaris Ventures
    • Prospect Venture Partners
    • Roche
    • Salix
    • Sandoz
    • Sanofi-Aventis
    • Santarus
    • Savient
    • Schering AG
    • Schering Plough
    • Schroder Ventures Life Sciences
    • Sepracor
    • Serono
    • Shire Pharmaceuticals
    • Sofamor
    • SouthWest Oncology
    • Synta
    • Techno Ventures Management
    • Telix
    • Transkaryotic
    • United Pharmaceuticals
    • Unither
    • Versant Ventures
    • Vertex
    • Vicuron Pharma
    • Village Ventures
    • WorldCom
    • Wyeth
    • Xenova
    • YM Biosciences